-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Maintains Outperform on Amgen, Raises Price Target to $372

Benzinga·12/03/2025 13:51:41
Listen to the news
BMO Capital analyst Evan David Seigerman maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $335 to $372.